利莫西拉克托巴西勒斯发酵KBL674 缓解阴道候群病
Sung Jae Jang1,2, Eun Jung Jo3, Cheonghoon Lee1,4
1Department of Environmental Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea.
Probiotics and antimicrobial proteins
|November 19, 2024
概括
菌 (L. fermentum) KBL674通过抑制Candida albicans的生长,有效地对抗阴道角膜病. 这种益生菌也对肠道微生物群的多样性产生了积极的影响,这表明预防酵母菌感染的双重机制.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 香菌是阴道香病的主要原因.
- 乳酸菌种在阴道微生物群中占主导地位,并保护人参菌病.
- 乳酸和过氧化是由Lactobacillus生产的关键抗菌剂.
研究的目的:
- 在小鼠模型中研究Limosilactobacillus fermentum (L. fermentum) KBL674对阴道候群病的影响.
- 确定L. fermentum KBL674是否可以抑制Candida albicans的生长和感染.
- 探索L. fermentum KBL674对肠道微生物群的影响及其与阴道角膜病的关系.
主要方法:
- 通过口服L. fermentum KBL674给阴道候群病的小鼠模型.
- 评估C. albicans的状细胞生长抑制.
- 评估阴道感染的严重程度,组织厚度和免疫细胞透.
- 肠道微生物组合的分析和与阴道C. albicans负担的相关性.
主要成果:
- L. fermentum KBL674 抑制了 C. albicans 的缺陷生长.
- 口服L. fermentum KBL674的使用显著减少了阴道C. albicans感染和症状.
- L. fermentum KBL674调节了肠道微生物群的多样性,增加了特定的细菌属和家族.
- 肠道细菌的数量与阴道C. albicans的负相关.
结论:
- L. fermentum KBL674显示出作为预防性阴道角膜病的预防剂的潜力.
- 益生菌通过直接抑制和肠道微生物组调节来减少阴道C. albicans负担.
- 肠道微生物组组成与阴道C. albicans负担有关,这表明有系统效应.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
134
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
134
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
01:18Surface Membrane Barriers
1.0K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.0K